Login to Your Account



Knowing When to Fold 'Em: Amicus Pompe Phase II Solid

By Randy Osborne
Staff Writer

Thursday, October 11, 2012
in_the_clinic.jpg

Positive preliminary data from a Phase II trial with Amicus Therapeutics Inc.'s drug chaperone in Pompe disease, unveiled at an Australian scientific meeting, tickled the company's share price, but investors must wait until year's end for the complete results.

Meanwhile, the company's lead compound, the chaperone Amigal (migalastat) for Fabry disease – subject of a deal retooled this summer by partner GlaxoSmithKline plc – will finish a Phase III registration study by the end of the year, too.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription